![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
E Donato di Paola, B Cusack, M Yamada and E Richelson
Department of Psychiatry, Mayo Clinic Jacksonville, Florida.
Clone N1E-115 cells have specific, high-affinity binding sites for neurotensin (NT). These receptors mediate formation of cyclic GMP and other second messengers. We studied the effects of extended exposure of cells to [D-Lys8]NT(8-13) (NT2), a peptidase-resistant NT analog, on NT's ability to stimulate cyclic GMP synthesis and to bind [3H]NT to its sites on these cells. When intact N1E-115 cells were preincubated with NT2 (1 microM) for various times (15 min to 12 hr) at 37 degrees C, maximal desensitization and binding site (Bmax) loss occurred after only 15 min. Receptor affinity for [3H]NT did not change. At 0 degrees C NT2 for 15 min caused no down-regulation. After 15 min of preincubation with NT2 at 37 degrees C, the recovery of receptor binding and function after a 10 to 20 min lag-time was rapid (T1/2 = 15 min and 19 min, for binding and cyclic GMP response, respectively). After 12 hr of NT2 preincubation, it was slow (T1/2 = 212 min). Incubation of cells with cycloheximide (70 microM) for 5 hr after their exposure to NT2 for 15 min did not change the rate or extent of recovery of NT Bmax. However, cycloheximide did decrease the recovery of NT Bmax after exposure of cells to NT2 for 12 hr. Cycloheximide alone did not change NT Bmax. These data suggest that this decrease of NT receptor binding after short (15 min) and long (12 hr) exposure times to agonist involves two consecutive steps: intracellular sequestration of recyclable NT receptors, followed by receptor degradation causing true down-regulation.
This article has been cited by other articles:
|
|
 |
|
  C. Norman, S. Beckett, C. Spicer, D. Ashton, X. Langlois, and G. Bennett Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion J Psychopharmacol, May 1, 2008; 22(3): 300 - 307. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Najimi, F. Souaze, M. Mendez, E. Hermans, T. Berbar, W. Rostene, and P. Forgez Activation of Receptor Gene Transcription Is Required to Maintain Cell Sensitization after Agonist Exposure. STUDY ON NEUROTENSIN RECEPTOR J. Biol. Chem., August 21, 1998; 273(34): 21634 - 21641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Souaze, W. Rostene, and P. Forgez Neurotensin Agonist Induces Differential Regulation of Neurotensin Receptor mRNA. IDENTIFICATION OF DISTINCT TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL MECHANISMS J. Biol. Chem., April 11, 1997; 272(15): 10087 - 10094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Calabresi, A. Siniscalchi, A. Pisani, A. Stefani, N. B. Mercuri, and G. Bernardi A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices Neurology, August 1, 1996; 47(2): 557 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Vossler, A. R. Wyler, R. J. Wilkus, G. Gardner-Walker, and B. W. Vlcek Cataplexy and monoamine oxidase deficiency in Norrie disease Neurology, May 1, 1996; 46(5): 1258 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Elliott, M. Brodsky, A. Hynansky, K. M. Foley, and C. E. Inturrisi Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance Neurology, December 1, 1995; 45(12_Suppl_8): S66 - S68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Gunderson The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care Neurology, March 1, 1995; 45(3): 569 - 572. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
